The GV-backed consumer goods marketplace hit a $2.8bn valuation in a Tiger Global-led series E round, which brings its total funding to $490m.

Rakuten, Progressive and GV-backed online lending platform developer floated at the bottom of its range before a first-day pop.

Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.

Pfizer Ventures-backed cancer drug developer BioAtla's shares popped on its first day of trading yesterday following a $189m initial public offering.

Blue Venture Fund returned as part of the latest funding to be raised by the mobile substance abuse treatment service.

Amazon Climate Pledge Fund and Shell Ventures both participated in a $21.4m round that will support development of ZeroAvia's hydrogen aircraft powertrain.

The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.

NAB, US Bancorp and Alphabet are set to exit payment processing technology provider Poynt in an acquisition sized at up to $365m.

Mayo Clinic had invested in and partnered the medical data software provider before joining a series C round also featuring NTTVC.

Intel will exit the digital loan documentation software publisher in a $279m all-cash acquisition by Wolters Kluwer.